Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Apr;55(4):385–388. doi: 10.1038/bjc.1987.77

Cancer in mice: effects of prednisolone or mepacrine alone and with cytotoxic drugs.

A Bennett, P B Melhuish, S Patel, H Randles, I F Stamford
PMCID: PMC2001699  PMID: 3580263

Abstract

WHT/Ht mice were transplanted s.c. with NC carcinoma, and the tumours were excised after 2 weeks. The mice were treated orally throughout the experiments with prednisolone 500 micrograms kg-1 or mepacrine 3.6 mg kg-1, starting the day after tumour transplantation or, with prednisolone, the day after tumour excision. In some experiments the mice were also treated with the cytotoxic drugs methotrexate 2 mg kg-1 and melphalan 1.4 mg kg-1. The excised tumours were weighed; some of them, and samples of serum, were extracted for prostanoids which were measured by radioimmunoassay. The chemotherapy lengthened the survival of the mice, but prednisolone or mepacrine had little or no effect on survival, metastasis, the response to chemotherapy, tumour size or the formation of tumour prostanoids.

Full text

PDF
385

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett A., Berstock D. A., Carroll M. A. Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Br J Cancer. 1982 May;45(5):762–768. doi: 10.1038/bjc.1982.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett A., Carroll M. A., Melhuish P. B., Stamford I. F. Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin. Br J Cancer. 1985 Aug;52(2):245–249. doi: 10.1038/bjc.1985.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennett A., Houghton J., Leaper D. J., Stamford I. F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins. 1979 Feb;17(2):179–191. doi: 10.1016/0090-6980(79)90037-6. [DOI] [PubMed] [Google Scholar]
  4. Bennett A., Stamford I. F., Unger W. G. Prostaglandin E2 and gastric acid secretion in man. J Physiol. 1973 Mar;229(2):349–360. doi: 10.1113/jphysiol.1973.sp010142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bombardieri S., Cattani P., Ciabattoni G., Di Munno O., Pasero G., Patrono C., Pinca E., Pugliese F. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol. 1981 Aug;73(4):893–901. doi: 10.1111/j.1476-5381.1981.tb08743.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deraedt R., Jouquey S., Delevallée F., Flahaut M. Release of prostaglandins E and F in an algogenic reaction and its inhibition. Eur J Pharmacol. 1980 Jan 11;61(1):17–24. doi: 10.1016/0014-2999(80)90377-5. [DOI] [PubMed] [Google Scholar]
  7. Dray F., McCall E., Youlten L. J. Failure of anti-inflammatory steroids to inhibit prostaglandin production by rat polymorphonuclear leucocytes. Br J Pharmacol. 1980 Feb;68(2):199–205. doi: 10.1111/j.1476-5381.1980.tb10408.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  9. Hennam J. F., Johnson D. A., Newton J. R., Collins W. P. Radioimmunoassay of prostaglandin F-2-alpha in peripheral venous plasma from men and women. Prostaglandins. 1974 Mar 25;5(6):531–542. doi: 10.1016/s0090-6980(74)80028-6. [DOI] [PubMed] [Google Scholar]
  10. Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Honn K. V., Busse W. D., Sloane B. F. Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem Pharmacol. 1983 Jan 1;32(1):1–11. doi: 10.1016/0006-2952(83)90644-5. [DOI] [PubMed] [Google Scholar]
  12. Honn K. V., Cicone B., Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 1981 Jun 12;212(4500):1270–1272. doi: 10.1126/science.7015512. [DOI] [PubMed] [Google Scholar]
  13. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  14. Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer. 1978 Oct;38(4):503–512. doi: 10.1038/bjc.1978.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nigam S., Becker R., Rosendahl U., Hammerstein J., Benedetto C., Barbero M., Slater T. F. The concentrations of 6-keto-PGF1 alpha and TXB2 in plasma samples from patients with benign and malignant tumours of the breast. Prostaglandins. 1985 Apr;29(4):513–528. doi: 10.1016/0090-6980(85)90076-0. [DOI] [PubMed] [Google Scholar]
  16. Shaw T., Chesterman C. N., Morgan F. J. In vitro synthesis of low molecular weight proteins in human platelets: absence of labelled release products. Thromb Res. 1984 Dec 15;36(6):619–631. doi: 10.1016/0049-3848(84)90201-9. [DOI] [PubMed] [Google Scholar]
  17. Stamford I. F., Melhuish P. B., Carroll M. A., Corrigan C. J., Patel S., Bennett A. Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation. Br J Cancer. 1986 Aug;54(2):257–263. doi: 10.1038/bjc.1986.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Unger W. G., Stamford I. F., Bennett A. Extraction of prostaglandins from human blood. Nature. 1971 Oct 1;233(5318):336–337. doi: 10.1038/233336b0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES